- Second-Quarter 2010 Revenues of $17.3 Billion
- Second-Quarter 2010 Reported Diluted EPS(1) of $0.31, Adjusted Diluted EPS(2) of $0.62
- Reaffirms 2010Financial Guidance and 2012 Financial Targets
- Strong Quarterly Performance Reflects More Balanced Business Mix and Product Portfolio
($ in millions, except per share amounts) | ||||||||||||||||||
Second-Quarter | Year-to-Date | |||||||||||||||||
2010 | 2009 | Change | 2010 | 2009 | Change | |||||||||||||
Reported Revenues | $ 17,327 | $ 10,984 | 58% | $ 34,077 | $ 21,851 | 56% | ||||||||||||
Reported Net Income(1) | 2,475 | 2,261 | 9% | 4,501 | 4,990 | (10%) | ||||||||||||
Reported Diluted EPS(1) | 0.31 | 0.34 | (9%) | 0.56 | 0.74 | (24%) | ||||||||||||
Adjusted Income(2) | 4,959 | 3,249 | 53% | 9,841 | 6,916 | 42% | ||||||||||||
Adjusted Diluted EPS(2) | 0.62 | 0.48 | 29% | 1.22 | 1.03 | 18% | ||||||||||||
See end of text prior to tables for notes. | ||||||||||||||||||
Pfizer Inc. (NYSE: PFE) today reported financial results for second-quarter 2010. Since the acquisition of Wyeth was completed on October 15, 2009, legacy Wyeth products and operations are reflected in the first two quarters of 2010, but not reflected in the first two quarters of 2009. Second-quarter 2010 revenues were $17.3 billion, an increase of 58% compared with $11.0 billion in the year-ago quarter. Revenues for second-quarter 2010 compared with the year-ago quarter were favorably impacted by $5.4 billion, or 50%, due to the addition of the legacy Wyeth products, by $315 million, or 3%, due to legacy Pfizer products, and by $584 million, or 5%, due to foreign exchange. For second-quarter 2010, U.S. revenues were $7.4 billion, an increase of 63% compared with the year-ago quarter. International revenues were $9.9 billion, an increase of 54% compared with the prior-year quarter, which reflected 45% operational growth and a 9% favorable impact of foreign exchange. U.S. revenues represented 43% of total revenues in second-quarter 2010 compared with 41% in the year-ago quarter, while international revenues represented 57% of total revenues in second-quarter 2010 compared with 59% in the year-ago quarter.
For first-half 2010, revenues were $34.1 billion, an increase of 56% compared with $21.9 billion in the same period in 2009. Revenues for first-half 2010 compared with the year-ago period were favorably impacted by $10.7 billion, or 49%, due to the addition of the legacy Wyeth products, by $173 million, or 1%, due to legacy Pfizer products, and by $1.3 billion, or 6%, due to foreign exchange. U.S. revenues were $14.7 billion, an increase of 55% compared with first-half 2009. International revenues were $19.4 billion, an increase of 57% compared with the same period last year, which reflected 46% operational growth and an 11% favorable impact of foreign exchange. U.S. revenues represented 43% and international revenues represented 57% of the total in first-half 2010, both comparable with first-half 2009.
Business Revenues
Pfizer operates two distinct commercial organizations: Biopharmaceutical and Diversified. Biopharmaceutical includes the Primary Care, Specialty Care, Established Products, Emerging Markets and Oncology customer-focused units, while Diversified includes Animal Health, Consumer Healthcare, Nutrition and Capsugel.
Second-Quarter(13) | |||||||||||||
Operational | |||||||||||||
($ in millions) | 2010 | 2009(13) | Change | Foreign | Total | Legacy Pfizer | |||||||
Primary Care(3) | $ 5,923 | $ 5,160 | 15% | 3% | 12% | 5% | |||||||
Specialty Care(4) | 3,769 | 1,423 | 165% | 5% | 160% | 8% | |||||||
Established Products(5) | 2,730 | 1,670 | 63% | 5% | 58% | (10%) | |||||||
Emerging Markets(6) | 2,250 | 1,455 | 55% | 11% | 44% | 11% | |||||||
Oncology(7) | 349 | 355 | (2%) | 2% | (4%) | (14%) | |||||||
Biopharmaceutical | 15,021 | 10,063 | 49% | 5% | 44% | 3% | |||||||
Animal Health(8) | |||||||||||||
